Cardioprotective benefits of carvedilol-CR [controlled-release] or valsartan added to lisinopril in patients with essential hypertension

Trial Profile

Cardioprotective benefits of carvedilol-CR [controlled-release] or valsartan added to lisinopril in patients with essential hypertension

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2011

At a glance

  • Drugs Carvedilol; Lisinopril; Valsartan
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 May 2011 Results presented at the 26th Annual Scientific Meeting of the American Society of Hypertension.
    • 24 May 2011 Results assessing efficacy under different cardiac loading conditions presented at the 26th Annual Scientific Meeting of the American Society of Hypertension.
    • 30 Jun 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top